VOR

Vor Biopharma Inc.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc. (VOR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B+
Factor Score 3.8 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
D-
Factor Score 0.9 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.1
EV / EBITDA -4.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -15.6%
Price Return 12M 93.0%
Catalyst Signal 0.00
Market Cap $1.2B
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B+ (3.8) C+ (2.7) D- (0.9) B (3.2) C+ (2.6) C+ (2.7)
2026-11-08 B+ (3.8) C+ (2.7) D- (0.9) C+ (2.8) C+ (2.6) C+ (2.6)
2026-11-01 A- (3.9) C+ (2.6) D- (0.8) B- (3.0) C+ (2.7) C+ (2.6)
2026-10-25 B+ (3.8) C+ (2.6) D- (0.9) B- (2.9) C+ (2.6) C+ (2.6)
2026-10-18 B+ (3.7) C+ (2.5) D- (0.9) B- (3.1) C+ (2.6) C+ (2.6)
Page 1 of 3